Updates to the guidelines for the diagnosis and management of multiple myeloma-Reference-Cited by-同舟云学术

Updates to the guidelines for the diagnosis and management of multiple myeloma

Published:2014-05-07 Issue:1 Volume:167 Page:131-133
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Pratt Guy¹²,Jenner Matthew³,Owen Roger⁴,Snowden John A.⁵,Ashcroft John⁴,Yong Kwee⁶,Feyler Sylvia⁴,Morgan Gareth⁷,Cavenagh Jamie⁸,Cook Gordon⁴,Low Eric⁹,Stern Simon¹⁰,Behrens Judith¹⁰,Davies Faith⁷,Bird Jennifer¹¹

Affiliation:

1. School of Cancer Studies; University of Birmingham; Birmingham UK

2. Department of Haematology; Heart of England NHS Foundation Trust; Birmingham UK

3. Department of Haematology; University Hospital Southampton NHS Foundation Trust; Southampton UK

4. Department of Haematology; Leeds Teaching Hospitals NHS Trust; Leeds UK

5. Department of Haematology; Royal Hallamshire Hospital; Sheffield UK

6. Department of Haematology; University College London Hospitals; London UK

7. Section of Haemato-Oncology; Institute of Cancer Research; London UK

8. Department of Haematology; Barts Health NHS Trust; London UK

9. Myeloma UK; Edinburgh UK

10. Department of Haematology; Epsom and St Heliers University Hospitals; London UK

11. Department of Haematology; University Hospitals Bristol NHS Foundation Trust; Bristol UK

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.12926/fullpdf

Reference10 articles.

1. Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma;Arnulf;Haematologica,2012

2. Haemato-oncology Task Force of British Committee for Standards in Haematology (BCSH) and UK Myeloma Forum. Guidelines for the diagnosis and management of multiple myeloma 2011;Bird;British Journal of Haematology,2011

3. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial;Boyd;Leukemia,2012

4. British Society of Blood & Marrow Transplantation Clinical Trials Committee. Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry;Cook;Biology of Blood and Marrow Transplantation,2011

5. A Second Autologous Stem Cell Transplant (ASCT2) induces superior durability of response (DuR) following bortezomib-containing re-induction therapy for relapsed multiple myeloma (MM): final results from the BSBMT/Ukmf Myeloma X (Intensive) Trial;Cook;Blood,2013

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of Minimal Residual Disease Status to Reduce Uncertainty in Estimating Long-term Survival Outcomes for Newly Diagnosed Multiple Myeloma Patients;Journal of Health Economics and Outcomes Research;2023-01-06

2. Use of Minimal Residual Disease Status to Reduce Uncertainty in Estimating Long-term Survival Outcomes for Newly Diagnosed Multiple Myeloma Patients;Journal of Health Economics and Outcomes Research;2023

3. Patient and Caregiver Experience Decision Factors in Treatment Decision Making: Results of a Systematic Literature Review of Multiple Myeloma Decision Aids;Value in Health;2023-01

4. Global patterns and trends in multiple myeloma incidence: Age, period and birth cohort analysis;2022-08-30

5. Evolution or revolution in multiple myeloma therapy and the role of the UK;British Journal of Haematology;2020-11